3413-28-3

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-Fluorophenoxy)piperidine is used as a building block for the synthesis of various pharmaceutical compounds due to its unique reactivity and pharmacological properties. It contributes to the development of new drugs with improved efficacy and safety profiles.
Used in Research and Development:
4-(4-Fluorophenoxy)piperidine is used as a research chemical for studying the structure-activity relationship of piperidine derivatives. This helps researchers understand the effects of different structural modifications on the biological activity of these compounds, leading to the discovery of more potent and selective drug candidates.
Used in Drug Discovery and Development:
The 4-fluorophenoxy group in 4-(4-Fluorophenoxy)piperidine provides unique reactivity, making it valuable for drug discovery and development. It can be used to design and synthesize novel compounds with potential therapeutic applications, enhancing the drug development process and contributing to the advancement of medicine.

InChI:InChI=1/C11H14FNO/c12-9-1-3-10(4-2-9)14-11-5-7-13-8-6-11/h1-4,11,13H,5-8H2

Upstream product

• 333954-85-1 tert-butyl 4-(4-fluorophenoxy)piperidine-1-carboxylate 
• 371-41-5 4-Fluorophenol 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 1972-28-7 diethylazodicarboxylate 

Downstream Products

• 1026504-07-3 4-(4-fluoro-phenoxy)-1-[4-(tetrahydro-pyran-2-yloxy)-phenyl]-piperidine 
• 354563-94-3 ((2S)-1-Benzylpyrrolidin-2-yl)-[4-(4-fluorophenoxy)-piperidin-1-yl]-methanone Hydrochloride 
• 944390-30-1 C₁₈H₁₅ClF₂N₂O₄ 
• 1094173-06-4 C₃₁H₃₆FN₃O₂ 
• 1229830-32-3 7-Benzyloxy-6-chloro-2-[4-(4-fluoro-phenoxy)-piperidine-1-carbonyl]-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic acid tert-butyl ester 
• 944390-57-2 C₁₈H₁₆F₂N₂O₄ 
• 330669-16-4 (R)-1-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-phenoxy]-3-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-propan-2-ol 
• 330669-31-3 (S)-1-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-phenoxy]-3-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-propan-2-ol 
• 63843-66-3 4-(4-fluoro-phenoxy)-1-[(2-methyl-indol-3-yl)-oxo-acetyl]-piperidine 
• 681509-02-4 4-[4-(4-fluorophenoxy)piperidin-1-yl]phenol 
• 63843-67-4 3-{2-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-ethyl}-2-methyl-indole 

Relevant academic research and scientific papers

Identification of a new series of benzothiazinone derivatives with excellent antitubercular activity and improved pharmacokinetic profiles

Nitrobenzothiazinone (BTZ) is a promising scaffold with potent activity against M. tuberculosis by inhibiting decaprenylphosphoryl-beta-d-ribose 2′-oxidase (DprE1). But unfavorable durability poses a challenge to further development of this class of agents. Herein, a series of BTZs bearing a variety of different substituents at the C-2 position were designed and synthesized. Compounds were screened for their antimycobacterial activity against Mycobacterium tuberculosis H37Ra and were profiled for metabolic stability, plasma protein-binding capacity and pharmacokinetics in vivo. In general, these new BTZs containing N-piperazine, N-piperidine or N-piperidone moiety have excellent antitubercular activity and low cytotoxicity. Several of the compounds showed improved microsomal stability and lower plasma protein-binding, opening a new direction for further lead optimization. And we obtained compound 3o, which maintained good anti-tuberculosis activity (MIC = 8 nM) and presented better in vitro ADME/T and in vivo pharmacokinetic profiles than reported BTZ compound PBTZ169, which may serve as a candidate for the treatment of tuberculosis.

DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS

Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

A COMPOUND AND A PHARMACEUTICAL COMPOUND FOR TREATMENT OF INFLAMMATORY DISEASES

The present invention relates to a compound and a pharmaceutical composition for treating inflammatory diseases, and the present invention is characterized by being a compound represented by chemical formula I or a pharmaceutically acceptable salt, hydrat

DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which contain, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 have the meanings given in claim 1, at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS

The present invention relates to derivatives of general formula I wherein : - W represents nitrogen, - R1 represents: ? a hydrogen or a linear or branched C1-C5 alkyl radical or, ? a C1-C3 alkyl radical substituted with groups such as trifluoromethyl, nitrile, hydroxy, C1-C3 alcoxy, C3-C6 alkoxyalkoxy, indolyl, thiophenyl, oxothiophenyl, C1-C3 N-alkylcarbamoyl groups or, ? a phenyl or pyridyl or naphthyl, or thiophenyl group optionally substituted with one or more groups such as halogen atoms, nitro, nitrile, trifluoromethyl, vinyl, methylsulfanyl, linear branched C1-C4 alkyl, linear or branched C1-C3 alkoxy groups, ? a C6 2-oxocycloalkyl radical - R2 represents a methyl or heptyl, - m, n are equal to 1, - V represents CH2, - X-Y represents -N- (C=O) -, -CH-O-, - Z represents a phenyl group substituted with one or more trifluoromethyl groups, halogen atoms or linear C1-C4 alkyl groups.

ETHER DERIVATIVES

The present invention relates to ether derivatives according to general formula I, and to their pharmaceutically-acceptable salts, which may be used in treating or preventing cognitive disorders, drug addiction, depression, anxiety, drug dependence, demen

Peptide compounds

The present invention relates to a compound of the formula (I)wherein R1 is benzofuranyl substituted by halogen, or styryl substituted by halogen; R2 is substituted hydroxy, substituted mercapto or substituted sulfonyl; and X is or pharmaceutically acceptable salts thereof. The compound (1) of the present invention and pharmaceutically acceptable salts thereof possess a strong inhibitory activity on the production of nitric oxide (NO), and are useful for prevention and/or treatment of NO-mediated diseases in human being and animals.

PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1ALPHA BINDING TO ITS RECEPTOR CCR1

A compound of the formula (I) wherein a, b, c R1, R2, R3, R4, R5, R6, R7, Q, W, Y, and Z are defined as above , useful as potent and selective inhibitors of MIP-1α (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes).